Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress

Core Insights - Aura Biosciences, Inc. is set to present additional Phase 1 data on bel-sar (AU-011) for non-muscle invasive bladder cancer (NMIBC) at the 40th Annual European Association of Urology (EAU) Congress in Madrid, Spain from March 21-24, 2025 [1] - The company will also host a virtual urologic oncology investor event on March 24, 2025, featuring key opinion leaders discussing ongoing clinical trials and future development plans [5][6] Presentation Details - The late-breaker presentation titled "Safety and efficacy of Bel-sar (AU-011), a Virus-like-Drug-Conjugate (VDC), in patients with Non-Muscle Invasive Bladder Cancer (NMIBC)" will be presented by Dr. Seth Lerner on March 22, 2025 [2] - The EAU Research Forum will feature a presentation on "Virus-like Drug Conjugates (VDC), a paradigm shifting approach for the treatment of bladder cancer" on March 23, 2025 [3][4] Investor Event - The virtual investor event will include discussions on the ongoing Phase 1 trial of bel-sar, focusing on its safety and feasibility as a monotherapy prior to transurethral resection of bladder tumor (TURBT) [5] - The event will also provide updates on the bladder cancer program, including plans for a Phase 1b/2 trial expansion [6] Company Overview - Aura Biosciences is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors, with its lead candidate bel-sar (AU-011) in late-stage development for primary choroidal melanoma and early-stage development in bladder cancer [12]